Patent is only the first part of inertia to overcome here. You need insurance companies to agree to refund your alternative. You need to get doctors to prescribe it. You need to get pharmacies to stock it. You need to get patients to want them. Only one of these groups has any incentive to help you.
This is why some countries have enacted laws to help with that.
And, laws that don't force the use of brand name drugs.
https://www.statnews.com/2016/08/25/mylan-antitrust-epipen-s...
Re:FDA slams EpiPen maker
by maxerickson on Friday September 08, 2017 @09:04AM
(#15199827)
The specific mechanism Mylan markets is covered by a patent. Some adjustment to the way the needle cap operates.
Of course that patent doesn't prevent other epinephrine autoinjectors from coming to market (and Adrenaclick is available in the US, including a couple generics).
My take is that the FDA should have some authority to deny market approval for such small improvements if the company refuses to license them to generic manufacturers. The hard part is deciding what constitutes a small improvement.
Not the market. The FDA.
If people start to pay attention to the process and the corruption surrounding EpiPen, will it blow the lid off the entire FDA system?
Re:FDA slams EpiPen maker
by emiliobumachar on Friday September 08, 2017 @06:38AM
(#15199200)
http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-dr...
"They keep trying, and the FDA keeps refusing to approve them for human use."
There is definitely a market failure here, but it's not clear why.